[FIG. 1]


Anti-Mesothelin
Anti-Mesothelin
Anti-CD3
CH2
CH2
CH3
CH3
Fc (Knob)
Fc (Hole)

[FIG. 2]


Anti-Mesothelin
Anti-EGFR
Anti-CD3
CH2
CH2
CH3
CH3
Fc (Knob)
Fc (Hole)

[FIG. 3]


mAU
62.50
32
30
28
26
24
22
20
18
16
14
12
10
8
6
4
2
0
-2
0
20
40
60
80
100
120
140
ml

[FIG. 4]


kDa
180
115
80
65

[FIG. 5]


mAU
61.67
60
55
50
45
40
35
30
25
20
15
10
5
0
0
20
40
60
80
100
120
140
ml

[FIG. 6]


kDa
180
115
80
65

[FIG. 7]


H226
30000
20000
10000
0
MFI
0
0.001
0.01
0.1
1
10
100
Antibody concentration (nM)
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 8]


AsPC-1
30000
20000
10000
0
MFI
0
0.001
0.01
0.1
1
10
100
Antibody concentration (nM)
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 9]


Jurkat
300
200
100
0
MFI
0
0.001
0.01
0.1
1
10
100
Antibody concentration (nM)
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 10]


Cell viability (%), 24hr (H226)
140
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 11]


Cell viability (%), 24hr (AsPC-1)
140
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 12]


Cell viability (%), 48hr (H226)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 13]


Cell viability (%), 48hr (AsPC-1)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 14]


Cell viability (%), 48hr (H226)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 15]


Cell viability (%), 48hr (AsPC-1)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 16]


Cell viability (%), 24hr (H226)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 17]


Cell viability (%), 48hr (H226)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 18]


Cell viability (%), 24hr (H226)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 19]


Cell viability (%), 48hr (H226)
120
100
80
60
40
20
0
0
0.1
1
10
100
1000
10000
Ab Conc. [pM]
Irrelevant/anti-CD3
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 20]


Tumor volume (mm3)
150
100
50
0
0
10
20
30
Days after tumor cell inoculation
PBS
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 21]


250
200
150
100
50
0
T/C % (median)
0
10
20
30
Days after tumor cell inoculation
PBS
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 22]



[FIG. 23]


400
300
200
100
0
Tumor volume (mm3)
0
10
20
30
40
Days after tumor cell inoculation
PBS
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 24]


AsPC1
150
100
50
0
T/C % (median)
0
10
20
30
40
Days after tumor cell inoculation
PBS
HMI323/HMI323-A15
Cetuximab/HMI323-A15

[FIG. 25]



[FIG. 26]


Cetuximab/HMI323-A15 IgG1
Mean plasma concentration (μg/ml)
100
10
1
0.1
0
100
200
300
400
500
600
700
800
Time (hr)

[FIG. 27]


HMI323/HMI323-A15 IgG1
Mean plasma concentration (μg/ml)
100
10
1
0.1
0
100
200
300
400
500
600
700
Time (hr)